Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
J Natl Cancer Inst
    March 2026
  1. ROSHANI S, Boekel NB, Van Leeuwen FE, Rademakers SE, et al
    Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patients.
    J Natl Cancer Inst. 2026 Mar 23:djag090. doi: 10.1093.
    >> Share

  2. NALINI M, O'Brien KM, Calafat AM, Wang L, et al
    Tobacco-related urinary biomarkers and lung cancer risk in women, a case-cohort analysis.
    J Natl Cancer Inst. 2026 Mar 18:djag078. doi: 10.1093.
    >> Share

  3. LIM H, Byun J, Ripley RT, Choi J, et al
    Methylation signatures distinguish non small cell lung cancer subtypes and associated with survival in smokers with lung squamous cell carcinoma.
    J Natl Cancer Inst. 2026 Mar 10:djag067. doi: 10.1093.
    >> Share

    February 2026
  4. POCOBELLI G, Del Vecchio NJ, Cushing-Haugen K, Kamineni A, et al
    Up-to-date prevalence at recommended ages for discontinuing routine colorectal, cervical and lung cancer screening.
    J Natl Cancer Inst. 2026 Feb 16:djag044. doi: 10.1093.
    >> Share

    January 2026
  5. CAO P, De Nijs K, Lee J, Jeon J, et al
    Performance of smoking duration-based lung cancer screening eligibility criteria: a comparative modeling study.
    J Natl Cancer Inst. 2026 Jan 23:djag018. doi: 10.1093.
    >> Share

  6. SAMET JM, Studts JL
    Lung cancer screening: are race- and risk-aware criteria needed?
    J Natl Cancer Inst. 2026 Jan 13:djaf328. doi: 10.1093.
    >> Share

  7. BAILEY JT, Chang CJ, Gaston SA, Jackson CL, et al
    Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers.
    J Natl Cancer Inst. 2026;118:94-101.
    >> Share

  8. WOOSTER M, May M, Agrawal P, Lee J, et al
    The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non-small cell lung cancer.
    J Natl Cancer Inst. 2026;118:49-57.
    >> Share

  9. BERRINGTON DE GONZALEZ A, Gunter MJ, Schubauer-Berigan MK, Garcia-Closas M, et al
    The multidimensional role of cancer epidemiology in cancer prevention: discovery science and beyond.
    J Natl Cancer Inst. 2026;118:18-25.
    >> Share

    December 2025
  10. MANFUL A, Mercaldo S, Blume JD, Aldrich MC, et al
    Addressing algorithmic bias in lung cancer screening eligibility.
    J Natl Cancer Inst. 2025 Dec 29:djaf298. doi: 10.1093.
    >> Share

    November 2025
  11. RAGER JB, Cao P, Hayward RA, Meza R, et al
    Personalizing lung cancer screening recommendations for heterogenous populations: a microsimulation study.
    J Natl Cancer Inst. 2025 Nov 3:djaf316. doi: 10.1093.
    >> Share

  12. SELLERS ME, Cronin KA, Lowy DR
    Stat Bite: Urban and Rural Lung Cancer Mortality Trends in the United States.
    J Natl Cancer Inst. 2025;117:2417-2418.
    >> Share

  13. NUCCIO A, Salomone F, Servetto A, Ricciuti B, et al
    Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis.
    J Natl Cancer Inst. 2025;117:2388-2393.
    >> Share

    October 2025
  14. KHOR S, Carlson JJ, Basu A, Bansal A, et al
    The association between new cancer therapy innovations and financial toxicity.
    J Natl Cancer Inst. 2025;117:2021-2028.
    >> Share

    September 2025
  15. HAAS JS, Todd KW, Mclerran D, Tiro JA, et al
    Gaps in care across the cancer screening continuum for cervical, colorectal and lung cancer.
    J Natl Cancer Inst. 2025 Sep 10:djaf248. doi: 10.1093.
    >> Share

  16. FAN Y, Jin R, Monterroza L, Liu X, et al
    Suppression of LKB1-mutant lung adenocarcinoma by natural killer cells from females.
    J Natl Cancer Inst. 2025;117:1858-1867.
    >> Share

    August 2025
  17. PATON EL, Cetnar JP, Freeman-Daily J, Feldman J, et al
    Landscape assessment of patient-reported outcome item coverage of tyrosine kinase inhibitor-associated adverse events.
    J Natl Cancer Inst. 2025;117:1664-1672.
    >> Share

  18. FULLER S, Alexeeff S, Caan B, Goncalves MD, et al
    Early identification of weight loss trajectories in advanced cancer and associations with survival.
    J Natl Cancer Inst. 2025;117:1729-1732.
    >> Share

    July 2025

  19. Correction to: Obesity-Specific Improvement of Lung Cancer Outcomes and Immunotherapy Efficacy with Metformin.
    J Natl Cancer Inst. 2025 Jul 28:djaf184. doi: 10.1093.
    >> Share

  20. ABURAKI R, Fujiwara Y, Haketa S, Horita N, et al
    Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis.
    J Natl Cancer Inst. 2025 Jul 24:djaf190. doi: 10.1093.
    >> Share

  21. LAVERY JA, Chen Y, Panageas KS, Wang Y, et al
    Unveiling non-small cell lung cancer treatment effect heterogeneity: a comparative analysis of statistical methods.
    J Natl Cancer Inst. 2025 Jul 10:djaf176. doi: 10.1093.
    >> Share

  22. XIA L, Pu Q, Kang R, Mei J, et al
    Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study).
    J Natl Cancer Inst. 2025;117:1474-1484.
    >> Share

  23. FAN Q, Dong W, Schafer EJ, Wagle NS, et al
    Changes in time-to-treatment initiation for breast, non-small cell lung, colon, or rectal cancers throughout the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2025;117:1506-1511.
    >> Share

    June 2025
  24. ZHANG J, Wang S, Li T, Liu X, et al
    RE: Efficacy and safety of personalized optimal programmed cell death 1 ligand combinations in advanced non-small cell lung cancer: a network meta-analysis.
    J Natl Cancer Inst. 2025 Jun 6:djaf132. doi: 10.1093.
    >> Share

    May 2025
  25. MCWILLIAM A, Marshall D, Kerns SL, Barnett GC, et al
    Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
    J Natl Cancer Inst. 2025;117:1018-1026.
    >> Share

    March 2025
  26. ZHOU P, Cui J, Sun R, Liu X, et al
    RE: Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake.
    J Natl Cancer Inst. 2025 Mar 27:djaf081. doi: 10.1093.
    >> Share

  27. MILDER CM, Cahoon EK, Schonfeld SJ, Preston DL, et al
    Sex-specific radiation-associated lung cancer mortality risks as impacted by smoking among US radiologic technologists.
    J Natl Cancer Inst. 2025 Mar 20:djaf064. doi: 10.1093.
    >> Share

  28. NOGUEIRA LM, Yabroff KR, Yates E, Shultz JM, et al
    Facility exposure to wildfire disasters and hospital length of stay following lung cancer surgery.
    J Natl Cancer Inst. 2025 Mar 11:djaf040. doi: 10.1093.
    >> Share

    February 2025
  29. HU P, Prorok PC, Katki HA
    Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.
    J Natl Cancer Inst. 2025;117:303-311.
    >> Share

    January 2025
  30. KANAYA N, Seddiq W, Chen KS, Kajiwara Y, et al
    Engineered allogeneic stem cells orchestrate T lymphocyte driven immunotherapy in immunosuppressive leptomeningeal brain metastasis.
    J Natl Cancer Inst. 2025 Jan 22:djaf006. doi: 10.1093.
    >> Share

  31. GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al
    Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
    J Natl Cancer Inst. 2025;117:188-197.
    >> Share

  32. TUMINELLO S, Turner WM, Untalan M, Ivic-Pavlicic T, et al
    Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake.
    J Natl Cancer Inst. 2025;117:112-119.
    >> Share

    November 2024
  33. GOMEZ SL, DeRouen M, Chen MS Jr, Wakelee H, et al
    Elevated risk of lung cancer among asian American females who have never smoked: an emerging cancer disparity.
    J Natl Cancer Inst. 2024 Nov 20:djae299. doi: 10.1093.
    >> Share

  34. SMITH RJ JR, Zollo R, Kalvapudi S, Vedire Y, et al
    Obesity-Specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin.
    J Natl Cancer Inst. 2024 Nov 19:djae295. doi: 10.1093.
    >> Share

    October 2024
  35. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    >> Share

  36. CHU X, Tian W, Ning J, Zhou R, et al
    Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis.
    J Natl Cancer Inst. 2024;116:1571-1586.
    >> Share

    September 2024
  37. PROSPER AE, Lin Y, Aberle DR
    Lung cancer screening with low-dose computed tomography-where do we go from here?
    J Natl Cancer Inst. 2024 Sep 16:djae197. doi: 10.1093.
    >> Share

    August 2024
  38. LIU Q, Medina HN, Koru-Sengul T, Rodriguez E, et al
    Intra-Ethnic and Geographic Disparities in Stage at Diagnosis for Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2024 Aug 21:djae199. doi: 10.1093.
    >> Share

  39. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    >> Share

    June 2024
  40. ZHANG EY, Cheung LC, Katki HA, Graubard BI, et al
    The risk and benefit profiles of US eligible lung cancer screening attendees vs. non-attendees.
    J Natl Cancer Inst. 2024 Jun 27:djae148. doi: 10.1093.
    >> Share

  41. HENDERSON LM, Durham DD, Gruden J, Pritchard M, et al
    Comparing characteristics of individuals screened for lung cancer with 2021 versus 2013 USPSTF recommendations.
    J Natl Cancer Inst. 2024 Jun 24:djae141. doi: 10.1093.
    >> Share

  42. WU X, Zhang B
    RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 8:djae130. doi: 10.1093.
    >> Share

  43. TAKI T, Ishii G
    RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 7:djae131. doi: 10.1093.
    >> Share

  44. SCHUZ J, Kovalevskiy E, Olsson A, Moissonnier M, et al
    Cancer mortality in chrysotile miners and millers, Russian Federation: main results (Asbest Chrysotile Cohort-Study).
    J Natl Cancer Inst. 2024;116:866-875.
    >> Share

  45. UPRETY D, Seaton R, Hadid T, Mamdani H, et al
    Racial and socioeconomic disparities in survival among patients with metastatic Non-Small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 3:djae118. doi: 10.1093.
    >> Share

    March 2024
  46. FUCITO LM, Palmer AM, Baldassarri SR
    A new perspective on mitigating lung cancer risks through smoking cessation and reduction.
    J Natl Cancer Inst. 2024 Mar 18:djae044. doi: 10.1093.
    >> Share

  47. NAGASAKI Y, Taki T, Nomura K, Tane K, et al
    Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Mar 8:djae053. doi: 10.1093.
    >> Share

    February 2024
  48. MOEN EL, Schmidt RO, Onega T, Brooks GA, et al
    Association between a network-based physician linchpin score and cancer patient mortality: a SEER-Medicare analysis.
    J Natl Cancer Inst. 2024;116:230-238.
    >> Share

  49. MEERNIK C, Raveendran Y, Kolarova M, Rahman F, et al
    Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review.
    J Natl Cancer Inst. 2024 Feb 6:djae026. doi: 10.1093.
    >> Share

    January 2024
  50. GUTIERREZ-TORRES DS, Kim S, Albanes D, Weinstein SJ, et al
    Changes in smoking use and subsequent lung cancer risk in the ATBC study.
    J Natl Cancer Inst. 2024 Jan 25:djae012. doi: 10.1093.
    >> Share

    December 2023
  51. SHIELS MS, Graubard BI, McNeel TS, Kahle L, et al
    Trends in smoking-attributable and smoking-unrelated lung cancer death rates in the U.S., 1991-2018.
    J Natl Cancer Inst. 2023 Dec 9:djad256. doi: 10.1093.
    >> Share

  52. BILLINGY NE, Tromp VNMF, Aaronson NK, Hoek RJA, et al
    Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial.
    J Natl Cancer Inst. 2023;115:1515-1525.
    >> Share

  53. ZUMSTEG ZS, Luu M, Rosenberg PS, Elrod JK, et al
    Global epidemiologic patterns of oropharyngeal cancer incidence trends.
    J Natl Cancer Inst. 2023;115:1544-1554.
    >> Share

    November 2023
  54. LEHRER S, Rheinstein PH
    Re: Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancers.
    J Natl Cancer Inst. 2023;115:1427-1428.
    >> Share

  55. LU K, Wang HC, Tu YC, Chang CC, et al
    Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer.
    J Natl Cancer Inst. 2023;115:1383-1391.
    >> Share

  56. EVANS JV, Suman S, Goruganthu MUL, Tchekneva EE, et al
    Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.
    J Natl Cancer Inst. 2023;115:1404-1419.
    >> Share

    September 2023
  57. KHODAYARI MOEZ E, Warkentin MT, Brhane Y, Lam S, et al
    Circulating proteome for pulmonary nodule malignancy.
    J Natl Cancer Inst. 2023;115:1060-1070.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016